Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

ABSTRACT:

Purpose

Prostate specific antigen velocity is an unreliable predictor of adverse pathology findings in patients on active surveillance for low risk prostate cancer. However, to our knowledge a new concept called prostate specific antigen velocity risk count, recently validated in a screening cohort, has not been investigated in an active surveillance cohort.

Materials and methods

We evaluated a cohort of men from 1995 to 2012 with prostate cancer on active surveillance. They had stage T1c disease, prostate specific antigen density less than 0.15 ng/ml, Gleason score 6 or less, 2 or fewer biopsy cores and 50% or less involvement of any core with cancer. The men were observed by semiannual prostate specific antigen measurements, digital rectal examinations and an annual survei

SUBMITTER: Patel HD 

PROVIDER: S-EPMC4711358 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature